Ikris Pharma
About Us Named Patient Program
Cities We Serve Contact Us
Aumolertinib

Sourced directly from the authorized manufacturer network to ensure authenticity and quality.

Ready to proceed? Order Aumolertinib on our secure patient portal to submit your prescription, upload documents and track your approval status.

Aumolertinib

Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.

Medicine Name: Aumolertinib
Generic Name (API): Aumolertinib Mesylate
Dosage Form & Strength: 55 mg
Route: Oral
Drug Class: Third-generation irreversible EGFR tyrosine kinase inhibitor (EGFR-TKI)

Manufacturer / Innovator:

Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

Regulatory Approval:

  • NMPA (China)
  • MHRA (UK)
Family enjoying life with Named Patient Program access

Your Trustworthy Partner For Named Patient Program

  • your trusted partner for named patient program

    Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.

  • 100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.

    100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.

  • Medicines sourced from authorized manufacturers with full batch traceability

    Medicines sourced from authorized manufacturers with full batch traceability.

  • EU-GDP Compliant Warehousing for secure, quality-controlled global distribution.

    EU-GDP compliant warehousing for secure, quality-controlled global distribution.

  • Temperature-Controlled Logistics for Safe and Timely Delivery

    Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.

GDP Compliant View Certificate
Licensed Wholesale distributor View Certificate

What Is Aumolertinib Used For?

Aumolertinib is a once-a-day tablet for non-small cell lung cancer (NSCLC) in adults whose tumour carries a change, or mutation, in the EGFR gene. It was developed and is made in China by Jiangsu Hansoh Pharmaceutical Group Co., Ltd., and is sold there as 阿美乐 (Ameile®). Outside China the brand name is Aumseqa®. Older papers call it almonertinib, its earlier name, and in trials it was coded HS-10296.

China's National Medical Products Administration (NMPA) first approved it in March 2020. It now has five approved uses in China, all for NSCLC with an EGFR mutation:

  • After an earlier EGFR tablet has stopped working: locally advanced or metastatic disease that has progressed on or after EGFR-TKI treatment and tests positive for the T790M resistance mutation (approved March 2020).
  • First-line treatment on its own: locally advanced or metastatic disease with an exon 19 deletion or the exon 21 (L858R) mutation (December 2021).
  • After chemoradiotherapy: locally advanced cancer that cannot be removed by surgery and has not grown after definitive platinum-based chemoradiotherapy, with an exon 19 deletion or L858R mutation (March 2025).
  • After surgery (adjuvant): stage II to IIIB cancer with an exon 19 deletion or L858R mutation after the tumour has been removed, with or without earlier adjuvant chemotherapy (May 2025).
  • First-line with chemotherapy: together with pemetrexed and platinum-based chemotherapy for locally advanced or metastatic disease with an exon 19 deletion or L858R mutation (January 2026).

A laboratory test must confirm the EGFR mutation before treatment starts. It is a prescription targeted cancer treatment and should be started and monitored by an oncologist.

How It Works

EGFR is a receptor on the surface of cells that tells them when to grow. In some lung cancers a mutation leaves this switch stuck in the "on" position, so the cancer keeps multiplying. This tablet is a third-generation EGFR tyrosine kinase inhibitor. It forms a lasting chemical bond with the faulty receptor, including the common exon 19 deletion and L858R forms and the T790M form that often makes earlier EGFR tablets stop working, while acting more weakly on normal EGFR. Animal studies suggest it can cross into the brain, which matters because lung cancer often spreads there.

What the Trials Showed

The main first-line study, AENEAS, was a phase 3 trial at 54 centres in China. It randomly assigned 429 people with untreated advanced EGFR-mutated NSCLC to this tablet or to an older, first-generation EGFR tablet. In the analysis reviewed by the European Medicines Agency, the median time before the cancer grew was 19.1 months, against 9.7 months with the comparison medicine (hazard ratio 0.46). Responses also lasted longer (a median of 18.1 against 8.3 months). Overall survival was 39.2 against 31.2 months, a difference that was not statistically significant.

A second study enrolled 244 people whose cancer had developed the T790M mutation after an earlier EGFR tablet. In this group, 65.6% saw their tumours shrink, as judged by independent reviewers.

Recommended Dosage

  • Usual dose: 110 mg (two 55 mg tablets) by mouth once a day, at about the same time each day, with or without food
  • How to take it: swallow the tablets whole with water; do not chew or crush them
  • Missed dose: take it the same day as soon as you remember, unless the next dose is due within 12 hours; never take two doses together
  • Lower dose: if side effects need it, the dose drops to 55 mg (one tablet) once a day; the European information also uses 55 mg when a strong CYP3A4-blocking medicine cannot be avoided
  • When it stops: lung inflammation or heart failure with symptoms means stopping for good; otherwise treatment carries on until the cancer grows or side effects become too hard to manage

For the after-surgery, after-chemoradiotherapy and chemotherapy-combination uses, your oncologist follows the Chinese prescribing information for the plan and the length of treatment.

This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.

Warnings and Precautions

The figures below come from 545 people who took 110 mg a day in the main studies, as summarised in the European assessment report. Most side effects were mild, but a few need quick action.

  • Lung inflammation (interstitial lung disease): seen in 2.9%. Report new or worse breathlessness, cough or fever straight away; if it is confirmed, the tablet is stopped permanently.
  • Heart rhythm: it can lengthen the QT interval on an ECG (9.4%). It should not be used by people born with long QT syndrome, with a family history of sudden cardiac death, or with a QTc above 500 ms. An ECG is done before starting, at least once in the first three weeks and later as needed, and blood salts are kept in range.
  • Heart pumping: heart failure or a drop in pumping strength was uncommon (0.7%). Tell your doctor about new swelling of the legs or unusual breathlessness.
  • Muscles: a rise in the muscle enzyme CPK was the most typical laboratory change (31.7%; severe in 7.5%), and muscle breakdown (rhabdomyolysis) occurred in 2.6%. Report muscle pain, weakness or dark urine.
  • Blood tests: raised liver enzyme AST (40.4%), low sodium (37.2%), a low white cell count (30.6%), raised creatinine (24.5%), low potassium (18.3%) and anaemia (18.0%) were common, so blood tests are repeated during treatment.
  • Blood clots: clots in the veins or lungs occurred in 7.2%. Seek help for a painful swollen leg, sudden chest pain or sudden breathlessness.
  • Eyes: dry eyes (3.5%) and blurred vision (2.6%) were reported; see an eye doctor if symptoms persist.

Other common effects: nose and throat infections (23.3%), skin rash (22.8%), urinary infections (18.3%), cough (15.4%), diarrhoea (13.2%), mouth sores (12.5%), vomiting (10.6%) and itching (10.5%). Compared with the older EGFR tablet in AENEAS, rash and diarrhoea were less frequent, while the CPK rise was more frequent.

Medicines and pregnancy: strong CYP3A4 inhibitors raise its blood level, and moderate or strong CYP3A4 inducers (including some tuberculosis and epilepsy medicines) lower it and are not recommended together. It can also weaken some hormonal contraceptives. Women who could become pregnant should avoid pregnancy during treatment and for 4 weeks after the last dose, using a non-hormonal method or adding a barrier method such as condoms. Safety in people under 18 has not been established. Always share a full list of your medicines and supplements with the oncologist.

How to Access Aumolertinib in India: A 6-Step Process

Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.

Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.

Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.

Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.

Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.

Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.

Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.

Documentation & Availability

What documents are required to import Aumolertinib to India?

Supply is arranged for one named patient, through the patient or the treating hospital, under India's rules for importing unapproved medicines. We usually ask for:

  • A prescription from a medical oncologist or chest oncologist naming the tablet and the dose
  • The biopsy report and the EGFR mutation test result (exon 19 deletion, L858R or T790M), with recent scan reports and a short note on earlier treatment
  • A government-issued photo ID of the patient

How is the order confirmed?

Once the prescription and test reports have been checked and, where needed, the import permit is in place.

Is Aumolertinib available in India?

Not yet. It has no marketing approval from CDSCO and cannot be bought from an Indian chemist. An Indian company has applied for permission to market it, but in 2026 the expert committee asked for more data, including a study in Indian patients, before it can be considered. It is not approved by the US FDA. It is approved in the United Kingdom (MHRA, June 2025). In the European Union it was approved in February 2026, but that licence was revoked in September 2026 over a data-protection point in the original filing, which the company describes as procedural. After a new application, the EMA's committee again recommended approval on 12 November 2026, and the final European decision is pending.

Until it is registered here, the Named Patient Program (NPP) offers a lawful route for one patient to import it on a doctor's prescription. We also help families with other China-approved EGFR tablets for lung cancer, such as befotertinib and rezivertinib for T790M-positive disease.

It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.

Sourcing & Delivery

NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The European assessment of the 55 mg tablet set storage at no more than 30°C in the original container, protected from moisture. For the Chinese packs we follow the instructions printed on the box, and the sealed cartons travel under temperature-controlled shipping. At the usual dose of two tablets a day, a month of treatment needs about 60 tablets, so we plan each shipment to cover a full month or more. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.

For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.

Availability Across Major Cities in India

Treatment with an EGFR tablet often continues for many months, so we plan a steady supply. After the oncologist's prescription and the EGFR report are checked and the import papers are ready, the tablets can reach the cities below and most other parts of the country.

Delhi

Chest and cancer specialists in Delhi see many patients with EGFR-positive lung cancer, and dispatch from New Delhi keeps delivery within the city quick.

Mumbai

Families in Mumbai can send the EGFR test report and prescription together, and we confirm which paperwork the import needs before quoting.

Bangalore

For patients in Bangalore taking the tablets at home, we schedule deliveries so the next month's supply arrives before the current box runs out.

Chennai

Oncologists in Chennai who have a confirmed T790M test result can request the tablets for a named patient.

Hyderabad

Patients in Hyderabad receive a written cost estimate first, and the order is placed only after the family agrees.

Kolkata

A caregiver in Kolkata or the north-east gets a message with the courier details as soon as the month's tablets leave our dispatch desk.

Pune

Patients in Pune who are moving on to the tablet after surgery or chemoradiotherapy can use the same documented import route.

Ahmedabad

The treating doctor in Ahmedabad can begin the request by sharing the biopsy and mutation reports with our team.

Vellore

In Vellore, where many patients come for scans and EGFR testing, the boxes can be sent to the hospital pharmacy ahead of the follow-up appointment.

Chandigarh

We deliver through Chandigarh to patients and hospitals in Punjab, Haryana and Himachal Pradesh.

Lucknow

For patients in Lucknow and the rest of Uttar Pradesh, the family can pick home delivery or delivery to the chest oncology clinic.

Kochi

Kerala patients on long-term treatment usually take a monthly parcel at Kochi, Kottayam or a town near home.

Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.

Author Details

Nitin Goswami

Written By

Nitin Goswami

Deputy Manager – Content & Social Media, Ikris Pharma Network

Sources: NMPA • CDSCO

Dr. Chirag C Shah

Medically Reviewed By

Dr. Chirag C Shah

MBBS

Last Updated: 19 November 2026

More Oncology Medicines

TRUSTED BY HEALTHCARE PROFESSIONALS & HOSPITALS

Need Help
Accessing Medicines?

Our specialists are here to guide you through every step of the medicine access process.

Let's us help!

Send us a message

Read how to access medicines

Read More arrow icon

Frequently Asked
Questions

Read More
Meet the NPP Assistant: ask us anything about NPP